Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp.
| Autor: | Pariser DM; Department of Dermatology, Eastern Virginia Medical School, and Virginia Clinical Research, Inc., Norfolk, Virginia; †DUSA Pharmaceuticals, Inc., A Sun Pharma Company, Wilmington, Massachusetts; ‡Therapeutics Inc., San Diego, California., Houlihan A, Ferdon MB, Berg JE |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] [Dermatol Surg] 2016 Mar; Vol. 42 (3), pp. 296-304. |
| DOI: | 10.1097/DSS.0000000000000630 |
| Abstrakt: | Background: Aminolevulinic acid photodynamic therapy (ALA-PDT) can be effective and well tolerated when applied over a broad area and for short drug incubation times. Objective: To evaluate the effect of short-incubation time and application method on the safety and efficacy of ALA-PDT versus vehicle (VEH-PDT) in the treatment of actinic keratoses (AKs) of the face or scalp. Methods: Aminolevulinic acid or VEH was applied to face or scalp as a broad area application for 1, 2, or 3 hours or as a spot application for 2 hours before blue light activation. An identical treatment was repeated at Week 8 if any AK lesions remained. Results: Median AK clearance rate for ALA-treated subjects ranged from 68% to 79% at Week 12, compared with 7% of the VEH-treated group (p < .0001). Complete clearance rate for ALA-treated subjects ranged from 17% (8/46) to 30% (14/47) at Week 12, compared with 2% (1/46) of the VEH-treated group (p = .0041). The safety profile seen in this study is consistent with previously reported side effects of the therapy. Conclusion: Short-incubation ALA-PDT was found to be superior to VEH-PDT for AK lesion clearance. A second treatment improves efficacy. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|